Lennox-Gastaut Syndrome Clinical Trial
Official title:
Double Blind, Randomised, Cross-over Study Melatonin Versus Placebo in the Lennox-Gastaut Syndrome: Neurophysiological and Neuropsychological Effects
Lennox-Gastaut syndrome is a severe epileptic encephalopathy of childhood. In that syndrome, various type of seizure occur, mainly tonic seizures, atonic seizures and atypical absences. The tonic seizure occur mostly at night. The hypothesis is that the melatonin could have a positive effect in that syndrome, by reducing the epileptic activity (assessed in the polysomnographic record by counting the number of interictal and ictal discharges) and stabilizing the structure of sleep. The study is double blind, randomised, cross-over designed.
The aim of the trial is to study the efficacity of melatonin in the Lennox-Gastaut syndrome, by assessing the reduction of the seizure/interictal discharges in polysomnography and assessing the sleep structure. After initial recruitment, the baseline visit includes a polysomnography. The patients will then be randomised in two groups: melatonin (1 cp containing melatonin 2 mg 1x/d 1h before sleep) vs placebo (1 cp 1x/d 1h before sleep). The treatment (melatonin or placebo) will be given for 1 month. After 1 month, the treatment will be stopped and another polysomnography will be recorded. The patients will take no treatment (wash-out period) for 15 days. The second treatment phase is cross-over: the group that had melatonin in the first phase will take placebo for one month, and the group that had placebo in the first treatment phase will take melatonin for one month. A last polysomnography will be recorded after the second treatment phase. The other medications (antiepileptic drugs) taken by the patients before the trial will not be modified. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT04133480 -
Investigation of Cognitive Outcomes With Cannabidiol Oral Solution
|
Phase 4 | |
| Recruiting |
NCT02632149 -
Trial to Assess Vagus Nerve Stimulation Therapy in Children With Lennox-Gastaut Syndrome
|
Phase 0 | |
| Active, not recruiting |
NCT05626634 -
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
|
Phase 2 | |
| Completed |
NCT01151540 -
A Long Term Extension Study of E2080 in Lennox-Gastaut Patients
|
Phase 3 | |
| Completed |
NCT00552045 -
Epilepsy Phenome/Genome Project
|
||
| Completed |
NCT00004776 -
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Topiramate for Lennox-Gastaut Syndrome
|
Phase 3 | |
| Withdrawn |
NCT03254680 -
Turmeric as Treatment in Epilepsy
|
N/A | |
| Completed |
NCT01146951 -
A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304)
|
Phase 3 | |
| Completed |
NCT01991041 -
European Registry of Anti-Epileptic Drug Use in Patients With Lennox-Gastaut Syndrome (LGS)
|
N/A | |
| Completed |
NCT01405053 -
Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs
|
Phase 3 | |
| Completed |
NCT02175173 -
Post-marketing Surveillance of Long-term Administration of Inovelon Tablets in Patients With Lennox-Gastaut Syndrome
|
||
| Completed |
NCT02224573 -
An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes
|
Phase 3 | |
| Completed |
NCT00004729 -
Ketogenic Diet for Child Epilepsy and Seizure Control
|
N/A | |
| Terminated |
NCT02815540 -
The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT02318537 -
Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome
|
Phase 3 | |
| Completed |
NCT01160770 -
Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome
|
Phase 3 | |
| Completed |
NCT03650452 -
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies
|
Phase 2 | |
| Completed |
NCT02731300 -
Transcranial Direct Current Stimulation, Treatment of Childhood Drug-Resistant Lennox-Gastaut Syndrome, A Pilot Study
|
Phase 4 | |
| Completed |
NCT02224690 -
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
|
Phase 3 |